Literature DB >> 23263379

p53 mutations in cancer.

Patricia A J Muller1, Karen H Vousden.   

Abstract

In the past fifteen years, it has become apparent that tumour-associated p53 mutations can provoke activities that are different to those resulting from simply loss of wild-type tumour-suppressing p53 function. Many of these mutant p53 proteins acquire oncogenic properties that enable them to promote invasion, metastasis, proliferation and cell survival. Here we highlight some of the emerging molecular mechanisms through which mutant p53 proteins can exert these oncogenic functions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23263379     DOI: 10.1038/ncb2641

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  102 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.

Authors:  Brittany Cross; Lihong Chen; Qian Cheng; Baozong Li; Zhi-Min Yuan; Jiandong Chen
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

4.  Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells.

Authors:  A L Kim; A J Raffo; P W Brandt-Rauf; M R Pincus; R Monaco; P Abarzua; R L Fine
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

5.  Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.

Authors:  Fabio Valenti; Francesca Fausti; Francesca Biagioni; Tal Shay; Giulia Fontemaggi; Eytan Domany; Michael B Yaffe; Sabrina Strano; Giovanni Blandino; Silvia Di Agostino
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

6.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

7.  Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Authors:  P M Neilsen; J E Noll; S Mattiske; C P Bracken; P A Gregory; R B Schulz; S P Lim; R Kumar; R J Suetani; G J Goodall; D F Callen
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

Review 8.  p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.

Authors:  G Melino
Journal:  Cell Death Differ       Date:  2011-07-15       Impact factor: 15.828

9.  TAp73 knockout shows genomic instability with infertility and tumor suppressor functions.

Authors:  Richard Tomasini; Katsuya Tsuchihara; Margareta Wilhelm; Masashi Fujitani; Alessandro Rufini; Carol C Cheung; Fatima Khan; Annick Itie-Youten; Andrew Wakeham; Ming-Sound Tsao; Juan L Iovanna; Jeremy Squire; Igor Jurisica; David Kaplan; Gerry Melino; Andrea Jurisicova; Tak W Mak
Journal:  Genes Dev       Date:  2008-09-19       Impact factor: 11.361

10.  Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

Authors:  P Dong; M Karaayvaz; N Jia; M Kaneuchi; J Hamada; H Watari; S Sudo; J Ju; N Sakuragi
Journal:  Oncogene       Date:  2012-07-30       Impact factor: 9.867

View more
  692 in total

1.  p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation.

Authors:  Natalia Artigas; Beatriz Gámez; Mónica Cubillos-Rojas; Cristina Sánchez-de Diego; José Antonio Valer; Gabriel Pons; José Luis Rosa; Francesc Ventura
Journal:  Cell Death Differ       Date:  2017-08-04       Impact factor: 15.828

Review 2.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

3.  Role of single-point mutations and deletions on transition temperatures in ideal proteinogenic heteropolymer chains in the gas phase.

Authors:  L Olivares-Quiroz
Journal:  Eur Biophys J       Date:  2016-01-27       Impact factor: 1.733

4.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

Review 5.  How do I kill thee? Let me count the ways: p53 regulates PARP-1 dependent necrosis.

Authors:  Rana Elkholi; Jerry E Chipuk
Journal:  Bioessays       Date:  2013-10-24       Impact factor: 4.345

6.  Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway.

Authors:  Lei Ji; Jinjin Xu; Jian Liu; Ali Amjad; Kun Zhang; Qingwu Liu; Lei Zhou; Jianru Xiao; Xiaotao Li
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

7.  Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.

Authors:  Kang Liu; Fang-Tsyr Lin; Joshua D Graves; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 8.  Metabolic Regulation of Apoptosis in Cancer.

Authors:  K Matsuura; K Canfield; W Feng; M Kurokawa
Journal:  Int Rev Cell Mol Biol       Date:  2016-07-30       Impact factor: 6.813

9.  The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.

Authors:  Saisai Wei; Hongbo Wang; Chunwan Lu; Sarah Malmut; Jianqiao Zhang; Shumei Ren; Guohua Yu; Wei Wang; Dale D Tang; Chunhong Yan
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

Review 10.  Probing the mechanisms underlying human diseases in making ribosomes.

Authors:  Katherine I Farley; Susan J Baserga
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.